HepCBC is seeking individual patient input for our submission to the federal government for an INTERFERON-FREE, ONE PILL/DAY drug combo, shown to be effective for genotypes 1, 3, 4, and 6, Merck Pharmaceutical's elbasvir + grazoprevir (± ribavirin). The treatment's success (96% - 100% SVR12) has been confirmed in trials including people considered 'hard to treat' including those who had failed previous treatment (including simeprevir, boceprevir, and telap
HepCBC is seeking individual patient input for our submission to the federal government for the first INTERFERON-FREE drug combo for GENOTYPE 4, AbbVie's "2D-GT4".ADD YOUR VOICE! We will be accepting input from anyone affected by hepatitis C (ALL GENOTYPES, not only Genotype 4) between Friday, Sept. 11 and midnight on Thursday, Sept. 25, 2015 through this confidential online form: PATIENT INPUT FORM for AbbVie 2D-GT4 Free WEBINAR about AbbVie 2D-GT4 availa
Link to July 3, 2014 WEBINAR about Sovaldi by Dr. Alnoor Ramji, co-hosted by HepCBC and the Pacific Hepatitis C Network. You just need to type in your name, email, etc. - no PW required. This webinar will only be online through July 14, 2014. To submit your voice to the Sovaldi (sofosbuvir) heptitis C drug review, please go to this page: http://hepcbc.ca/2014/07/sovaldi-bc/ . Sovaldi is produced by Gilead Sciences.
Link to July 3, 2014 WEBINAR about Sovaldi by Dr. Alnoor Ramji, co-hosted by HepCBC and the Pacific Hepatitis C Network If you want BC PharmaCare to cover sofosbuvir (SOVALDI™) treatment (from Gilead Sciences), read carefully: HepCBC needs to send BC PharmaCare a really good patient group submission. We need your help before July 10th. This is incredibly important, and every voice we can include makes our submission better, plus the greater number of voice
HCV Advocate in the USA has just published an excellent fact sheet on the new hepatitis C combo from AbbVie for genotype 1. Note this treatment is still unavailable in Canada, except in an approved clinical trial. Read factsheet:http://www.hcvadvocate.org/hepatitis/factsheets_pdf/Phase_3_Genotype_1_AbbVie.pdf
HCV Advocate in the USA has just published an excellent fact sheet on the new hepatitis C combo from Gilead, sofosbuvir (SOVALDI) and ledipasvir for genotype 1 only. Note ledipasvir alone, or in this or any other combination, is still unavailable in Canada, except in an approved clinical trial. Read factsheet:http://www.hcvadvocate.org/hepatitis/factsheets_pdf/Phase_3_Genotype_1_SOF-LDV.pdf
Simeprevir (GALEXOS) is also now covered on the Quebec formulary, according to CATIE, the Canadian AIDS Treatment Information Exchange. However, it is only available to those who have already failed conventional treatment with interferon and ribavirin. It is available only to genotype 1 patients who do not have the Q80K mutation and not co-infected with HIV. MUST MEET ALL THESE QUALIFICATIONS TO GET REIMBURSED FOR SIMEPREVIR: -- to be used in association w